Evidence map›Paper›PMID 42706330›Full record

ArticleAnalytical and bioanalytical chemistry2026

Quantitative method comparison in non-targeted analysis using cascade classification.

Nimesh P R Ranasinghe Arachchige, Kanti Sapkota, Omar Rivera, Krishna Patel, H Jamie Kim, Milani Patabandige, Thilini Perera, Joshua A Young

Abstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nimesh P R Ranasinghe ArachchigeU.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.ORCID http://orcid.org/0000-0002-6817-2795
Kanti SapkotaU.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.ORCID http://orcid.org/0000-0002-0189-6668
Omar RiveraU.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.ORCID http://orcid.org/0009-0007-1871-8968
Krishna PatelU.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.ORCID http://orcid.org/0009-0009-6046-6164
H Jamie KimU.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.ORCID http://orcid.org/0000-0002-0343-7406
Milani PatabandigeU.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.ORCID http://orcid.org/0000-0003-1084-9887
Thilini PereraU.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.ORCID http://orcid.org/0000-0002-0452-945X
Joshua A YoungU.S. Food and Drug Administration, Silver Spring, MD, 20993, USA. joshua.young@fda.hhs.gov.ORCID http://orcid.org/0000-0003-4454-0909

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

Non-targeted analysis (NTA) lacks consistent processes for comparing method performance across different analytical conditions. As a result, method comparison between NTA methods is often dependent on the chemicals detected in a particular study, making it difficult to objectively evaluate how instrumental performance influences the overall detectable space. Here, we describe a two-stage cascade classification approach that treats detectability as a binary outcome defined by experimental retention behavior and signal-to-noise criteria and characterizes the boundary between detectable and non-detectable chemical space using receiver operating characteristic (ROC) analysis. In Stage 1, compounds are filtered by estimated retention index to establish chromatographic accessibility. In Stage 2, detectability is classified using the electron impact cross-section (Q), with the classification threshold selected to satisfy a minimum recall constraint (recall ≥ 0.80). Using this treatment for the detectable space, the area under the ROC curve (AUC) emerges as a method-level figure of merit. Applied to two GC-MS systems operating under identical chromatographic conditions but with different mass selective detectors (Agilent 6890/5975B and 8890/5977C), the approach yielded Stage 2 AUC values of 0.659 (95% CI: 0.536-0.788) for Method A and 0.842 (95% CI: 0.702-0.933) for Method B at 10 μg/mL, quantitatively capturing the performance difference between instruments. The minimum-recall criterion selected near-identical classification thresholds for both methods (τ = 19.18 and 19.30, respectively), indicating that Q estimates essentially the same detectable chemical space for both instruments, and that the observed difference in detectable space reflects instrument performance. This approach provides a reproducible and transparent basis for GC-MS method comparison in NTA and refines the statistical basis needed for a generalized analytical evaluation of NTA methods.

Indexed as

Chemical spaceGas chromatography–mass spectrometryMethod comparisonNon-targeted analysis

Identifiers

PMID42706330
PMCPMC13577316

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.